Bright Ocean Pharmaceutical has obtained the exclusive distribution rights of the albumin product Ambomei in mainland China.

On November 4, 2025, Baiyang Pharmaceutical announced that the company had signed a deepening cooperation agreement with the multinational blood products company Jettbelin. According to the agreement, Baiyang Pharmaceutical will obtain the exclusive promotion, sales, and distribution rights for Jettbelin's human albumin product Ambomei in specific markets within China.